- KR₩2tn
- KR₩2tn
- KR₩425bn
Brief: Hugel Q3 Operating Profit 18 Billion Won, Down 62% From Year Earlier
Brief: Hugel Reports Q2 2026 Net Sales Up 25.1% TO KRW 137.90 Billion
Brief: Hugel Q4 Operating Profit 58.6 Billion Won, Up 26% From Year Earlier
Brief: Hugel Q3 Operating Profit 47.4 Billion Won, Down 11% From Year Earlier
Brief: Hugel Posts Q2 Net Sales Of KRW110.3 Bln
Brief: Hugel Inc To Retire 300,000 Common Shares
Brief: Hugel Q1 Operating Profit 39 Billion Won, Up 62.6% From Year Earlier
Brief: Hugel Q4 Operating Profit 46.6 Billion Won, Up 27% From Year Earlier
Brief: Hugel Inc Q3 Operating Profit 53 Billion Won, Up 55% From Year Earlier
Brief: Hugel To Divest 4.4 Billion Won Worth Of Own Shares
Brief: Hugel Q2 Consolidated Operating Profit 42.4 Billion Won, Up 51.6% From Year Earlier
Brief: Hugel Q1 Operating Profit 24 Billion Won, Up 29.5% From Year Earlier
Brief: Hugel Receives US FDA Approval For Its Neurotoxin Letybo
Brief: Hugel Q4 Operating Profit 37 Billion Won, Up 22% From Year Earlier
Brief: Hugel To Cancel 54.6 Billion Won Worth Of Own Shares
Brief: Hugel Q3 Operating Profit 34.6 Billion Won, Up 39.5% From Year Earlier
Brief: Hugel Resubmits BLA For Its Botulinum Toxin, Letybo To The U.S. FDA
Brief: Hugel Q2 Operating Profit 28 Billion Won, Up 27.5% From Year Earlier
Brief: Hugel Inc Q1 Operating Profit 19 Billion Won, Down 24.9% From Year Earlier